Literature DB >> 19414599

Ral overactivation in malignant peripheral nerve sheath tumors.

Vidya Bodempudi1, Farnaz Yamoutpoor, Weihong Pan, Arkadiusz Z Dudek, Tuba Esfandyari, Mark Piedra, Dusica Babovick-Vuksanovic, Richard A Woo, Victor F Mautner, Lan Kluwe, D Wade Clapp, George H De Vries, Stacey L Thomas, Andreas Kurtz, Luis F Parada, Faris Farassati.   

Abstract

Ras leads an important signaling pathway that is deregulated in neurofibromatosis type 1 and malignant peripheral nerve sheath tumor (MPNST). In this study, we show that overactivation of Ras and many of its downstream effectors occurred in only a fraction of MPNST cell lines. RalA, however, was overactivated in all MPNST cells and tumor samples compared to nontransformed Schwann cells. Silencing Ral or inhibiting it with a dominant-negative Ral (Ral S28N) caused a significant reduction in proliferation, invasiveness, and in vivo tumorigenicity of MPNST cells. Silencing Ral also reduced the expression of epithelial mesenchymal transition markers. Expression of the NF1-GTPase-related domain (NF1-GRD) diminished the levels of Ral activation, implicating a role for neurofibromin in regulating RalA activation. NF1-GRD treatment caused a significant decrease in proliferation, invasiveness, and cell cycle progression, but cell death increased. We propose Ral overactivation as a novel cell signaling abnormality in MPNST that leads to important biological outcomes with translational ramifications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414599      PMCID: PMC2704746          DOI: 10.1128/MCB.01153-08

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  72 in total

Review 1.  Ral-GTPases: approaching their 15 minutes of fame.

Authors:  Larry A Feig
Journal:  Trends Cell Biol       Date:  2003-08       Impact factor: 20.808

Review 2.  Neurofibromin: a general outlook.

Authors:  A B Trovó-Marqui; E H Tajara
Journal:  Clin Genet       Date:  2006-07       Impact factor: 4.438

Review 3.  Neurofibromatosis 1.

Authors:  Timothy M Lynch; David H Gutmann
Journal:  Neurol Clin       Date:  2002-08       Impact factor: 3.806

4.  Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors.

Authors:  R A Lothe; B Smith-Sørensen; M Hektoen; A E Stenwig; N Mandahl; G Saeter; F Mertens
Journal:  Genes Chromosomes Cancer       Date:  2001-02       Impact factor: 5.006

5.  A negative feedback signaling network underlies oncogene-induced senescence.

Authors:  Stéphanie Courtois-Cox; Sybil M Genther Williams; Elizabeth E Reczek; Bryan W Johnson; Lauren T McGillicuddy; Cory M Johannessen; Pablo E Hollstein; Mia MacCollin; Karen Cichowski
Journal:  Cancer Cell       Date:  2006-12       Impact factor: 31.743

6.  RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases.

Authors:  J A Aguirre-Ghiso; P Frankel; E F Farias; Z Lu; H Jiang; A Olsen; L A Feig; E B de Kier Joffe; D A Foster
Journal:  Oncogene       Date:  1999-08-19       Impact factor: 9.867

7.  Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?

Authors:  Eva A Turley; Mandana Veiseh; Derek C Radisky; Mina J Bissell
Journal:  Nat Clin Pract Oncol       Date:  2008-03-18

Review 8.  Transitions between epithelial and mesenchymal states in development and disease.

Authors:  Buzz Baum; Jeffrey Settleman; Margaret P Quinlan
Journal:  Semin Cell Dev Biol       Date:  2008-02-09       Impact factor: 7.727

9.  NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity.

Authors:  Teresa Corral; María Jiménez; Inmaculada Hernández-Muñoz; Ignacio Pérez de Castro; Angel Pellicer
Journal:  J Cell Physiol       Date:  2003-11       Impact factor: 6.384

Review 10.  Ras/Raf/ERK signalling and NF1.

Authors:  Marie C Harrisingh; Alison C Lloyd
Journal:  Cell Cycle       Date:  2004-10-17       Impact factor: 4.534

View more
  25 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

2.  RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC).

Authors:  Mohamad Ezzeldin; Emma Borrego-Diaz; Mohammad Taha; Tuba Esfandyari; Amanda L Wise; Warner Peng; Alex Rouyanian; Atabak Asvadi Kermani; Mina Soleimani; Elham Patrad; Kristina Lialyte; Kun Wang; Stephen Williamson; Bashar Abdulkarim; Mojtaba Olyaee; Faris Farassati
Journal:  Mol Oncol       Date:  2014-04-13       Impact factor: 6.603

Review 3.  The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer.

Authors:  Sunny Guin; Dan Theodorescu
Journal:  Acta Pharmacol Sin       Date:  2015-01-05       Impact factor: 6.150

4.  Overactivation of Ras signaling pathway in CD133+ MPNST cells.

Authors:  Emma Borrego-Diaz; Kaoru Terai; Kristina Lialyte; Amanda L Wise; Tuba Esfandyari; Fariba Behbod; Victor F Mautner; Melanie Spyra; Sarah Taylor; Luis F Parada; Meena Upadhyaya; Faris Farassati
Journal:  J Neurooncol       Date:  2012-04-08       Impact factor: 4.130

5.  The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery.

Authors:  Nicole F Neel; Timothy D Martin; Jeran K Stratford; Tanya P Zand; David J Reiner; Channing J Der
Journal:  Genes Cancer       Date:  2011-03

6.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Authors:  Walter J Jessen; Shyra J Miller; Edwin Jousma; Jianqiang Wu; Tilat A Rizvi; Meghan E Brundage; David Eaves; Brigitte Widemann; Mi-Ok Kim; Eva Dombi; Jessica Sabo; Atira Hardiman Dudley; Michiko Niwa-Kawakita; Grier P Page; Marco Giovannini; Bruce J Aronow; Timothy P Cripe; Nancy Ratner
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

7.  RalA is overactivated in medulloblastoma.

Authors:  Kevin F Ginn; Ben Fangman; Kaoru Terai; Amanda Wise; Daniel Ziazadeh; Kushal Shah; Robyn Gartrell; Brandon Ricke; Kyle Kimura; Sharad Mathur; Emma Borrego-Diaz; Faris Farassati
Journal:  J Neurooncol       Date:  2016-08-26       Impact factor: 4.130

8.  Ral activation promotes melanomagenesis.

Authors:  P A Zipfel; D C Brady; D F Kashatus; B D Ancrile; D S Tyler; C M Counter
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

Review 9.  Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame.

Authors:  Leanna R Gentry; Timothy D Martin; David J Reiner; Channing J Der
Journal:  Biochim Biophys Acta       Date:  2014-09-16

Review 10.  RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer.

Authors:  Chao Yan; Dan Theodorescu
Journal:  Pharmacol Rev       Date:  2018-01       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.